ERBB2 Exon 20 Insertion
Associated Genetic Biomarkers
ERBB2 Exon 20 Insertion is a predictive biomarker for use of trastuzumab emtansine in patients.
There are 1 NCCN guidelines that support the use of a targeted therapy based on the presence of ERBB2 Exon 20 Insertion.
Non-small cell lung carcinoma has the most therapies targeted against ERBB2 Exon 20 Insertion or its related pathways .
Trastuzumab Emtansine +
Non-Small Cell Lung Carcinoma -
|Biomarker Criteria:||Predicted Response: Primary Sensitivity|
|Clinical Setting(s): Metastatic (NCCN)|
|Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN.|
ERBB2 Exon 20 Insertion serves as an inclusion eligibility criterion in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 Exon 20 Insertion as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (4 open).
Trials with ERBB2 Exon 20 Insertion in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
Tarloxotinib bromide, egfr/her2 inhibitor ap32788, docetaxel, pertuzumab, and trastuzumab are the most frequent therapies in trials with ERBB2 Exon 20 Insertion as an inclusion criteria .
Significance of ERBB2 Exon 20 Insertion in Diseases
Non-Small Cell Lung Carcinoma +
ERBB2 is mutated in 4.12% of non-small cell lung carcinoma patients .
ERBB2 Exon 20 Insertion is an inclusion criterion in 5 clinical trials for non-small cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 Exon 20 Insertion and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (4 open) .
Trastuzumab emtansine is currently approved for use in patients with ERBB2 Exon 20 Insertion in non-small cell lung carcinoma .
Tarloxotinib bromide, egfr/her2 inhibitor ap32788, and docetaxel are the most frequent therapies in trials for non-small cell lung carcinoma that contain ERBB2 Exon 20 Insertion .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.